StockData

Gelteq vs Vyome

GELS and HIND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GELS and HIND compare

Vyome scores higher on the StockData Score (1 against 0 for Gelteq), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGELSHIND
Size and price
Market cap–$10.8M
Share price$0.269$1.54
Change, 1 year−73.0%−68.3%
Change, 5 years–−100.0%
Beta (5Y)1.351.60
Employees–18
StockData Score
Total score01 (better)
Valuation score00
Growth score00
Performance score00
Health score01 (better)
Dividend score00
Valuation
P/S–83.6×
Growth
Revenue growth (TTM)–−67.1%
Revenue growth, 5Y average–−51.0%
Profitability
Gross margin30.3%52.7% (better)
Operating margin−3318% (better)−9190%
Net margin–−8717%
FCF margin−3335%–
Return on equity–−194%
Return on invested capital–−173%
Financial health
Interest coverage−2.8× (better)−285.8×
Current ratio0.094.37 (better)
Altman Z-score–−13.57
Piotroski F-score–4
Dividends and buybacks
Buyback yield–39.6%
Shareholder yield–39.6%
Ownership
Held by institutions–2.0%
Held by insiders14.0%6.8%
Short interest, % of float–0.28%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.